Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

PMV Pharmaceuticals Reports Positive Ovarian Cancer Phase 2 Data and NDA Plans | WAPE

FilingSEC EDGAR8-K

PMV Pharmaceuticals Reports Positive Ovarian Cancer Phase 2 Data and NDA Plans

Aug 31, 2026, 16:06 ET · SEC accepted

StagePhase 2

Filing content

The company reported a 46% objective response rate in its Phase 2 ovarian cancer trial and plans to submit an NDA in Q1 2027.

AI summary of the filing. Please also check the source.

Related companies

PMV Pharmaceuticals, Inc.PMVPView stock

Analyzed by WAPE AI.

Preparing English content…

Comments —

Comment

Loading comments…